A family of (nested) dose-response models is introduced herein that can be used for describing the change in any continuous endpoint as a function of dose. A member from this family of models may be selected using the likelihood ratio test as a criterion, to prevent overparameterization. The proposed methodology provides for a formal approach of model selection, and a transparent way of assessing the benchmark dose. Apart from a number of natural constraints, the model expressions follow from an obvious way of quantifying differences in sensitivity between populations. As a consequence, dose-response data that relate to both sexes can be efficiently analyzed by incorporating the data from both sexes in the same analysis, even if the sexes are not equally sensitive to the compound studied. The idea of differences in sensitivity is closely related to the assessment factors used in risk assessment. Thus, the models are directly applicable to estimating such factors, if data concerning populations to be compared are available. Such information is valuable for further validation or adjustment of default assessment factors, as well as for informing distributional assessment factors in a probabilistic risk assessment. The various applications of the proposed methodology are illustrated by real data sets.
In the field of risk assessment the common way of analyzing dose-response data from animal studies is by statistically testing each dose group against the controls, resulting in a no observed adverse effect level (NOAEL). Because of various serious objections against this approach, Crump (1984) introduced the "benchmark dose" as an alternative to the NOAEL. In the benchmark approach a dose-response model is fitted to the data, and this model is used for estimating the dose at a certain level of response. Although the benchmark approach is gaining attention from toxicologists and risk assessors, its implementation in practice is still limited. One of the main practical difficulties of the benchmark approach is the quantification of the level of response that can be considered as biologically insignificant, or as acceptable from a risk management perspective. A second difficulty concerns the choice of the model to be fitted to the dose-response data. As yet, virtually no biologically based dose-response models for noncancer effects are available. Therefore, the benchmark approach has to rely on purely descriptive dose-response models. Clearly, numerous descriptive dose-response models can be fabricated, and the goodness of fit is usually the only criterion for deciding that one model is better than another. However, various alternative models may be found that equally satisfy the goodness of fit criterion for a particular data set. This is a serious problem as different models fitted to the same data may result in different benchmark doses. Therefore, the benchmark approach would be much improved if a formal procedure were available to guide the choice of model, ensuring that a particular data set yields reproducible results, so that the estimated benchmark dose can be regarded as an objectively assessed value.
This article proposes a family of dose-response models, together with a formal method to decide which member of this family of models will be used for describing any particular data set. As will be shown, the formulation of the proposed models follows directly from a number of desirable properties that are imposed by both biological and risk assessment considerations. A number of examples will illustrate the various applications of these models. In all examples benchmark doses (CEDs) are given, but it should be noted that the methodology discussed here also applies to the analysis of dose-response data that serve to answer a particular scientific question without being directly related to quantitative risk assessment.
Critical Effect Dose and Continuous Data
Toxicological observations may be reported as quantal, as ordinal, or as continuous data. In the toxicological literature the benchmark approach is often applied to and discussed for quantal data (e.g., Allen et al., 1994; Faustman et al., 1994) . Accordingly, the benchmark response is usually defined in terms of a response rate, in particular a given increase in incidence of a particular effect. It can be shown (Slob, in preparation) that this approach is problematic, due to the fact that experimental errors interfere with response rates that are observed in or estimated from experimental studies.
For continuous data this problem does not arise. Here, the dose-response relationship can be estimated separately from the experimental error (reflected by the variation in the observations within dose groups). A second fundamental difference is that a continuous dose-response relationship represents the change of the size of the effect with dose. It is thus natural to define the benchmark response for continuous data in terms of a particular effect size, but there are various ways of doing this. Some authors have proposed to define effect size relative to the "natural" variation in the controls (Crump, 1995; Gaylor and Slikker, 1990) . However, in a typical toxicity study (using inbred animals) the variation in the observations mainly reflects the heterogeneity in the experimental conditions. Normally, we try to minimize the experimental variation in toxicity studies, and the "natural" variation that we observe in any such study quantifies the extent to which we did not succeed in that. Clearly, this is not natural variation in any biological sense, and therefore it cannot serve as a standard in defining the benchmark response. This issue is further addressed elsewhere (Slob, in preparation) .
Instead of using the observed variation as a reference, the benchmark response can be defined in a biologically meaningful way as a particular change in the size of the effect that is considered acceptable or without adverse consequences for the subject. A toxicity study only allows for estimating the size of the effect (as a function of dose) as shown by the test animal under the average of all experimental conditions associated with the particular study. From a biological point of view the most natural way of measuring an effect size is in terms of a percent change relative to the background value of the particular endpoint.
To distinguish terminology from that currently used for quantal data, Slob and Pieters (1998) introduced the terms Critical Effect Size (CES) and Critical Effect Dose (CED) for continuous data. The CES reflects the quantitative change in a particular endpoint considered as nonadverse or acceptable, at the level of the individual organism. For instance, one might postulate that inhibition of cholinesterase of less than 20% is nonadverse for an individual, i.e.,
where f(CED) and f(0) denote the ChE activity (according to the model f ) at dose CED and at dose 0, respectively. Murrel et al. (1998) proposed another way of measuring the continuous benchmark response, viz. relative to the range between maximum and background response. The advantage of this approach would be that in this way a single numerical value, e.g., 10%, might be considered valid for different endpoints. Indeed, it does seem reasonable to take the maximum response level into account. For instance, a given percent change (CES) would most likely be less serious for a serum enzyme, which may increase 2-or 3-fold at high exposures, than it would be for relative liver weight, which typically has a much lower maximum response. However, it is better to let this aspect play a role in choosing a percent change (CES) for any particular endpoint, and maintain the freedom to take other considerations into account as well (e.g., normal fluctuations within individuals, biological meaning of the endpoint). A practical drawback of Murrel's definition is that it is often impossible to estimate the maximum response level due to insufficient data.
A General Family of Models
For most toxicological (continuous) endpoints no dose-response models are available that have been derived from the underlying biological mechanisms. Given this situation one has to resort to purely descriptive models. However, numerous descriptive models can be devised that are all suitable for fitting dose-response data. Yet, even though knowledge on the underlying biological mechanisms is usually poor, not all models may be considered equally plausible for mimicking the true dose-response relationship. Further, not all models are equally suitable in serving the purposes of risk assessment. The following considerations are relevant in developing a generic family of dose-response models to be used for analyzing doseresponse data from toxicity tests.
(1) To begin with, toxicological (continuous) measurements are nonnegative, and models allowing negative responses are unrealistic. These models should not be used, even when the fitted model only reaches negative values outside the range of observation. For that reason the often used polynomial functions (y ϭ a ϩ bx ϩ cx 2 ϩ . . .) will be excluded. (One of the reasons for the popularity of this family of models was ease of calculation, but this has become less compelling with modern computers.) The reader might note here that growth data could be negative, e.g., when for each animal initial body weight is subtracted from body weight after exposure. However, since small and large animals are likely to respond proportionally to a given treatment rather than by a similar absolute change, it makes more sense to measure growth by the ratio of body weight over initial body weight.
(2) Another fundamental choice is to exclude threshold models. The first reason is that the existence of dose-thresholds in a strict sense is hard to defend in dose-response relationships. In the case of continuous endpoints one necessary condition for a dose-response relationship with a threshold would be that all individual animals have exactly the same dosethreshold for that endpoint. This is highly unlikely, even in a highly controlled experiment with inbred animals. A second reason is that the estimation of the threshold as a parameter in a model is problematic: depending on the start values (see Appendix) of the model's parameters different estimates may result from the estimation procedure. The issue of dose-thresholds was extensively discussed elsewhere (Slob, 1999) . Instead of using threshold models-in the strict sense-threshold-like dose-response relationships may be described by smooth functions that are sufficiently curved (e.g., sigmoidal). Such functions allow the assessment of a dose associated with any small effect. Therefore, a generic family of models must include functions that have the flexibility to take on a sufficiently curved shape for describing threshold-like dose-response relationships.
(3) An important issue in toxicology and risk assessment is that of relative sensitivity between different populations, e.g., between test animals and humans, between average individual and sensitive individual, or between sexes. Therefore it would be convenient if relative sensitivity is reflected by one of the model's parameters. Before defining the concept of relative sensitivity, we first need to make explicit what we mean by "equally sensitive." Clearly, we would demand that the response is equal for all doses. This is obvious for two populations that do not differ in the background value of a particular endpoint. However, if they do differ, this background value needs to be taken into account. For example, body weights are usually different between sexes. An equal response in both sexes will now be defined as:
Thus, if the relative change compared to the background value is the same for all doses, males and females are considered equally sensitive regarding the particular endpoint. To express this idea in a dose-response model, it needs to be of the form:
instead of y ϭ a ϩ f(x), which is a more usual way of incorporating the background value in a regression function. Equation 1 reflects the idea that two different subpopulations may differ in the background value a (e.g., body weight), but nonetheless can be characterized by the same dose-response function f(x), in which case they are considered equally sensitive. The next question to be answered is how to express differences in sensitivity. The most convenient way of doing this appears to be in terms of a dose factor (potency factor or toxicity equivalence factor). Such a factor is consistent with the concept of assessment factors (also termed safety, uncertainty, or extrapolation factors), and if suitable data are available these factors can thus be directly estimated. Therefore, the general dose-response model should obey
(4) Next, a decision must be made on the function f(x) in Equation 2. It should, of course, obey f(0) ϭ 1, which can be achieved by exponential functions.
(5) A family of models is needed having the property that, for any particular dataset, an appropriate member can be chosen in a formal way. Therefore, it is convenient to work with a family of nested models, so that their fits can be compared using the likelihood ratio test (see section Further Statistical Methods).
(6) The family of models should include models that level off. Also it should contain models that change very little at low doses but that do change at higher doses (to mimic thresholdlike responses).
Taken all together these conditions suggest the following family of models:
where y is any continuous endpoint, and x denotes the dose. In all models the parameter a represents the level of the endpoint at dose 0, and b can be considered as the parameter reflecting the efficacy of the chemical (or the sensitivity of the subject). At high doses Models 4 and 5 level off to the value ac, so the parameter c can be interpreted as the maximum relative change. Models 3 and 5 have the flexibility to mimic thresholdlike responses. All these models are nested to each other, except Models 3 and 4, which both have three parameters. These two models cannot be compared to each other by a likelihood ratio test, and other considerations must be used to make a choice between them (see Illustrative Example 4).
In all models the parameter a is constrained to being positive for obvious reasons (it denotes the value of the endpoint at dose 0). The parameter d is constrained to values larger than (or equal to) 1, to prevent the slope of the function at dose 0 being infinite, which seems biologically implausible. The parameter b is constrained to be positive in all models. Parameter c in Models 4 and 5 determines whether the function increases or decreases, by being larger or smaller than unity, respectively. To make Model 3 a decreasing function a minus sign has to be inserted in the exponent. Figure 1 illustrates the separate members of this family of models, and how they are related to each other. For example, Model 2 is nested within Model 3, i.e., Model 2 is a special case of Model 3, as can be seen by setting d ϭ 1. Vice versa, Model 3 can be considered as an extension of Model 2, by incorporating the parameter d. As another example, Model 5 can be regarded as an extension of Model 2, by adding two more parameters (c and d).
Further Statistical Methods

Assumptions
As a default, it is assumed that the measurements are lognormally distributed. Consequently, the dose-response model is fitted on the log-scale, i.e., both the model and the data are log-transformed. After fitting the model, both the model and the data may be backtransformed to the original scale for purposes of plotting. Therefore, the group means are not arithmetic but geometric means (the geometric mean estimates the median of the lognormal distribution; see Slob, 1987) . Accordingly, the fitted model describes the median endpoint as a function of dose. Variances are assumed to be homogeneous (on log-scale) among dose groups. To detect gross violations of both normality and homogeneity of variances (on log-scale) one may plot the data (and the fitted model) on the logresponse scale. The contribution of any observation y to the log-likelihood function is given by 0.5 * { -ln(var) -[log(y/ f(x))] 2 /var }, where var denotes the variance of log(y). Observations below the detection limit contribute to the log-likelihood function by the natural logarithm of ⌽(log(detlim) -log(f(x)) / ͌var), where ⌽ denotes the standard normal distribution function (i.e., cumulative distribution). The letter expression is the probability of an observation to be smaller than the detection limit. Zero observations can also be accounted for in this way without any difficulty. Note that the models in this article only apply to endpoints that are assumed to always have a nonzero value, so that zero observations give the information that the value was somewhere below the detection limit (but still positive). It should be kept in mind that these models do not apply to endpoints that are assumed to be 0 at dose 0, such as internal dose as a function of external dose.
When a dose-response model is fitted to two (or more) subpopulations simultaneously, the methodology presented here allows for testing the homogeneity of variances between the subpopulations, as described below.
Likelihood Ratio Test
The likelihood ratio test may be used to test if extension of a model by increasing the number of parameters results in a statistically significant improvement of the fit. It can be shown that twice the difference of the log-likelihoods associated with the two model fits (approximately) follows a chi-square distribution, with the number of degrees of freedom equal to the difference in the number of parameters in both models. Table  1 shows the critical (␣ ϭ 0.05) difference in the two loglikelihood values, as a function of the number of degrees of freedom, i.e., the difference in the number of parameters between the two models.
Precision of Estimated Parameters and CED
The precision of the estimated regression parameters and of the CED can be assessed in various ways. For example, one might assess the variance-covariance matrix, and assume normal distributions for the estimated parameters to obtain confidence intervals. However, it is doubtful that the normality assumption is realistic, and the profile-likelihood method appears more reliable. Yet another approach is the bootstrap method, which is easily implemented and should give reliable Note. When the difference exceeds the critical value, the fit of the model with more parameters is better at a 5%-significance level. The number of degrees of freedom (df) is equal to the difference in the number of estimated parameters between both models. results. However, the calculations are time-consuming. We have recently compared the latter two methods by computer simulations, and they appear to result in similar intervals (Moerbeek and Slob, submitted) .
No Individual Data Available
In reported studies individual observations are usually not given. Instead, means and SDs (or standard errors of the mean) for each dose group are commonly reported. Since the mean and SD are "sufficient" statistics for a sample from a normal distribution, a dose-response model can just as well be fitted based on these statistics without any loss of information (except possible outliers). However, the normality assumption is not plausible, and it is better to assume lognormality. In that case sufficient statistics are provided by the geometric mean and the geometric SD, or by the (arithmetic) mean and SD on log-scale. These can be estimated from the reported mean and SD as follows:
where z ϭ ln(y). The contribution (score) of a particular treatment group to the log-likelihood is then given by
where n denotes the group size, E(z) the value (on log-scale) of the dose-response model at the relevant dose, V(z) the residual variance (on log-scale). E(z) (or rather the underlying regression parameters) and V(z) are the parameters to be estimated. Note that in plotting the model, it can be transferred to the original scale by the antilog. The plotted function then relates to the reconstructed geometric means, and not to the originally reported arithmetic means.
Selecting a Member from the Model Family
The nested character of the proposed family of models makes it possible to formally choose a model for describing a particular data set. In general, when a model is extended by one or more parameters the resulting fit criterion will achieve a higher value (or at least remain equal), as compared to the model with fewer parameters. However, it is unfavorable to use a model with too many parameters, as this results in reduced precision of model predictions. Therefore, a formal criterion is needed to decide whether any extension in the number of parameters should be accepted or not. For nested models this can easily be done by the likelihood ratio test, and an obvious formal decision criterion is the 5% significance level using this test. Thus, the model can be formally selected by consecutively fitting the members of the model family and choose the model that cannot be significantly improved by a model having more parameters, as determined by the likelihood ratio test.
Illustrative example 1. For illustrative purposes an extraordinarily complete set of dose-response data will be considered first. The data concern fetal weights as a function of po exposure to butyl benzyl phthalate (BBP) in maternal animals during gestation (Piersma et al., 2000) . These data are plotted in Figure 2 , with three members of the model family consecutively fitted to them. The log-likelihoods associated with all 5 models are given in Table 2 . Comparing Model 2 with Model 1 (no response) results in an enormous increase in the loglikelihood, not leaving any doubt regarding the existence of an effect of BBP on fetal weights. Since Model 2 has only one parameter more than Model 1, a difference of 1.92 would already be sufficient for significance at the 5% level (see Table  1 ). Further, it can be seen that Model 3 performs significantly better than Model 2, while Model 5 on its turn performs better than Model 3. Model 4, however, does not lead to any improvement compared to Model 2 (indeed, parameter c was estimated to be 0 here).
One might wonder if even better fits could be obtained by fitting a model with more than 5 parameters as in Model 5. Indeed, fitting the "maximum" model, i.e., a model consisting of 8 (geometric) means, one for each dose group, plus a common (geometric) variance, gives a log-likelihood value that is 6.51 units higher, with 4 more parameters. This is higher than the critical value of 4.74 associated with 4 more parameters (see Table 1 ), so one might conclude that Model 5 could still be improved in describing the dose-response relationship here. However, as Figure 2 shows, the deviations from the fitted Model 5 have no relation with dose, and therefore it is most likely that systematic differences between the dose groups occur that are caused by other factors than the dose. Although in this particular experiment much attention was given to randomization, it is virtually impossible to fully randomize an experiment in practice. For instance, administration of the dose was done per dose group. Although it is not difficult to randomize the order of dose groups (with a different order for each day), it is impractical to randomize the order of administration over all animals, irrespective of the dose group. Therefore, it may be concluded that Model 5 gives an accurate description of the true dose-response relationship.
Parenthetically, in this analysis it was assumed that the fetal weights are independent, which was in fact not the case (fetuses from the same mother were correlated). However, for point estimation of the parameters this has only minimal consequences, unless the design is highly unbalanced. In establishing confidence intervals the intraclass correlations should not be ignored and be taken into account in the statistical analysis.
Illustrative example 2. The sigmoid dose-response relationship as found in Figure 2 agrees with what toxicologists generally expect: at low doses the response is negligible, and at higher doses the response levels off. However, a 28-day study on Rhodorsil Silane resulted in close to linear dose-response relationships for all continuous endpoints considered (Woutersen et al., 2001) . Figure 3 shows the dose-response data for one of the endpoints measured in this study, viz. red blood cell counts, illustrating that the proposed family of models, despite being nonlinear, is flexible enough to cover (nearly) linear dose-response relationships. One may note that this example further illustrates that assumptions on thresholds or threshold mechanisms for noncancer endpoints may not be valid in general. Further, this example illustrates that the NOAEL will decrease with increasing sample sizes, while the CED (point estimate) remains stable.
Modeling Subpopulations
Analysis of Both Sexes in Animal Studies
In current analyses of dose-response data from animal studies (using the NOAEL approach) it is common to analyze male and female data separately, as for many endpoints both sexes already show differences when nonexposed. A dose-response analysis allows for a more efficient analysis of the data. In studies where both sexes have been observed, one may fit the same model to both sexes simultaneously, and examine which of the parameters depend on sex. In this way, an adequate description of the dose-response in both sexes may be achieved using fewer parameters than when the model is fitted to each sex separately. The gain of estimating fewer parameters is a smaller confidence interval for any prediction made by the model, including the CED.
Suppose, for example, that both sexes respond by the same relative decrease in body weight at any given dose of a particular compound. In that case one may consider both sexes as equally responding to the compound (with respect to body weight). Because of the nature of the proposed models, one can describe the dose-response relationship in both sexes by the same member of the model family, by only assuming a different value for the parameter a in both sexes, e.g., for Model 5 we have
Fetal weights as a function of dose (BBP) administered to the maternal animals during gestation. The small circles denote individual observations, the larger circles the (geometric) group means. The 3 panels show fitted models with an increasing number of parameters. The associated increase in the log-likelihood is significant, and Model 5 (lower panel) is chosen as the model to describe these data (see Table 2 ).
with a i ϭ a m for males, and a i ϭ a f for females. One may statistically test whether the use of a sex-dependent value for a results in a significantly better fit compared to the situation of a being equal in both sexes by the likelihood ratio test with one degree of freedom (since one more parameter needs to be estimated).
Next, consider the situation that both sexes are not equally sensitive to the compound with respect to body weight. In that case we make parameter b sex dependent, in addition to parameter a. We then again have one more parameter to be estimated, and it can be tested if the associated log-likelihood has significantly increased, using the likelihood ratio test with one degree of freedom.
Of course, it could be that fitting the model to both sexes separately is even better. This can be tested by comparing the sum of the two log-likelihoods associated with the separate fits, with the likelihood of the simultaneous fit, taking account of the difference in the total number of parameters estimated in both situations. For example, fitting Model 5 to both sexes separately involves a total of 10 parameters (4 regression parameters and one variance for each sex), while a simultaneous fit with both a and b sex dependent comprises 7 parameters. Therefore, the log-likelihood for the separate fits should be at least 3.91 larger than the simultaneous fit to be significantly better (see Table 1 ).
Illustrative example 3. Figure 4 shows the individual (rat) body weights at the end of a chronic study as a function of the applied dose. Clearly, male and female rats differ in body weights, and there is no need to statistically test this difference. Note. The number of parameters in the second column includes the (residual) variance. The maximum model consists of 8 geometric means (1 for each dose group) plus the variance; see Figure 2 . No. pars., number of parameters. Significant, p ϭ 0.05.
FIG. 3.
Red blood cell counts as a function of dose after a 28-day po study. The small circles denote individual observations, the larger circles the (geometric) group means. The CED 05 is estimated at 88.9 mg/kg, with 90%-confidence interval 82.4 -96.5 mg/kg.
FIG. 4. Individual body weights as a function of dose (
10 log-scale). The small symbols denote the individual observations, the larger symbols the (geometric) group means. Circles, males; triangles, females. Here Model 2 with sex-dependent a and sex-dependent variance is selected as the best description of these data, based on a comparison of log-likelihoods (see Table  3 ). The CED 05 is estimated at 9.7, with 90%-confidence interval 8.30 -11.74 dose units.
The first step of the analysis, that of choosing a member of the model family, can be performed by assuming parameter a being sex dependent right away. While Model 2 results in a clearly significantly better log-likelihood compared to Model 1 (no response), Models 3 and 4 do not add anything to the fit (see Table 3 ). Therefore, Model 2 may be selected for this data set. Next, Model 2 is fitted to males and females separately. The sum of the associated log-likelihoods (375.57, 6 parameters, 3 for each sex) is compared to the simultaneous fit with parameter a sex-dependent (365.42, 4 parameters). The difference between these two values is clearly significant (⌬loglik ϭ 10.15, df ϭ 2). Therefore, the model is fitted with b sexdependent as well, resulting in an only marginally higher log-likelihood (365.99) compared to situation that b is the same for both sexes. It may be concluded that males and females do not appear to differ in sensitivity. Finally, the model is fitted by assuming that, next to a, also the residual variation differs between sexes. This fit results in a log-likelihood of 375.07, only marginally smaller than the sum of the separate analysis, so this model is selected for describing this data set (see Fig. 4 ). Figure 5 shows cholesterol levels measured at 4 dose levels (including the controls), and Table 4 summarizes the log-likelihood results. When pooling the responses in males and females, the fit of Model 2 is significantly better than that of Model 1, while Model 3 is significantly better than Model 2 (see column "none"). However, Model 4 is better as well, and its likelihood is very similar to that of Model 3. These two models are not nested, and it is not possible to statistically test which one is better. However, Model 3 was fitted without the constraint that parameter d should be larger than 1, resulting in an estimate of 0.26 for this data set. This example illustrates that Model 3 with d Ͻ 1 is highly implausible, given the infinite slope of the function at dose 0. Such is implausible for any effect, but particularly for noncancer effects, where extremely low doses are expected to have virtually no effect at all. Refitting Model 3 with the constraint d Ͼ 1 resulted in exactly the same fit as Model 2. For this reason Model 4 will be chosen for a further analysis.
Illustrative example 4.
Parameter a being dependent on sex does not yield a significantly better fit, but parameter b does. The latter fit is not significantly poorer than the sum of the likelihoods per sex, and model 4 with sex-dependent b may be considered as the favorable model here (see Fig. 6 ). For completeness, this model may be extended with sex-dependent variance, but the increase in likelihood is not significant.
According to this analysis the males are more sensitive than the females, while the background cholesterol levels are similar in both sexes.
It should be noted that in this example the sum of the separate fits for males and females results in a log-likelihood that is, although not significantly, nonetheless considerably higher. Indeed, considering the fact that the geometric means in Figure 6 do not coincide with the fitted model very well, one might wonder if the model is close to the true dose-response relationship. So, the question remains here if the deviations of the means from the model are "real" or due to experimental error (note the large variation and the small number of animals). By deciding the latter (based on the nonsignificant likelihood ratio test), the deviations of the means from the model are taken into account in the statistical analysis as additional uncertainty, resulting in wider confidence intervals for the CED.
Illustrative example 5. When fitting a dose-response model to dose-response data from a published study one usually has to do with the reported (arithmetic) means and SDs (or standard errors of the mean) for each treatment group. These are "sufficient" statistics for a sample from a normal distribution, and one may fit a dose-response model to these statistics instead of to the individual data. (Of course, an analysis of outliers is not possible anymore.) However, it is more plausible to assume lognormality, and in that case the geometric means and geometric standard deviations are the proper (and sufficient) statistics. The latter two statistics can be estimated from the former two (see section Further Statistical Methods), but this procedure will not give identical results to direct estimation from the individual data. Nonetheless, the resulting inaccuracies may be negligible. To illustrate this, the data of the Illustrative Example 3 were reanalyzed based on the reported (arithmetic) means and SDs instead of on the individual data. Table 5 shows that the same model would be selected, with a similar fit result (compare Figs. 4 and 7) .
Analysis of Experimental Factors
The same methodology of analyzing dose-response data for male and female animals can be used to examine the influence of experimental factors. For example, one may wish to examine the influence of the diet on the dose-response relationship. Or, in further examining the toxicological mechanism, one may coexpose the animals to a chemical that is known to have a specific effect, such as inhibiting a particular enzyme. Or one may wish to examine the influence of exposure duration. The dose-response methodology as discussed here has the important advantage that adding extra experimental factors in the study design does not necessarily lead to a substantial increase Note. The likelihood associated with the selected model is printed in italics. See Figure 6 .
FIG. 6.
Cholesterol measured in males (circles) and female (triangles), as a function of dose. The dose is on 10 log-scale, with the controls plotted at an arbitrary level (indicated by -Inf). Note that males are more sensitive than females, resulting in a more than 4-fold lower CED. In this rather poor data set the 90%-confidence intervals for the CED 10 are rather wide: 4.9 -56.6, and 43. 6 -241.5 dose units, respectively. in the required number of animals. In a dose-response approach the statistical precision of the experiment is determined by the total number of animals used, rather than by the number of animals in a single treatment group.
Illustrative example 6. Figure 8 shows the cholinesterase (ChE) activity measured in plasma after 1, 2, and 4 months of exposure to an OP-ester. The process of model selection resulted in Model 5 with parameters a and b both dependent on time. The fact that parameter a is significantly different between the three points in time implies that the (background) ChE activity changes with age of the animals. The dependence of b on time can be interpreted as an effect of the OP-ester: with increasing exposure the dose-response curve gets steeper, i.e., the ChE inhibition increases with exposure duration. Accordingly, the CED decreases with increasing exposure duration.
Assessment of a CED Ratio
The extrapolation from surrogate data, such as the extrapolation of a nonadverse dose level for a particular animal strain to the sensitive human being, is a central problem in virtually any human health risk assessment. The current use of default uncertainty, or assessment factors (of 10, usually) is practical but far from satisfactory. Attempts have been made to find historical data to support default values (e.g., Hattis et al., 1999; Kramer et al., 1996; Pieters et al., 1998; Rulis and Hattan, 1985; Vermeire et al., 1999; Weil and McCollister, 
Note. The likelihood associated with the selected model is printed in bold. In this analysis, based on means and SDs, the same model is selected as in the analysis based on the individual data (see Table 3 ). See Figure 7 .
FIG. 7.
Fitted dose-response model for a situation where only arithmetic means and SDs for each treatment group are available. The symbols indicate the geometric means calculated from the arithmetic mean and SD (see Further Statistical Methods section). The estimated parameters are very similar to those obtained from an analysis of the individual data (see Fig. 4 ). Based on these data the 90%-confidence interval for CED 05 was estimated at 8.34 -11.59 dose units. Circles, males; triangles, females.
FIG. 8.
Cholinesterase inhibition as a function of dose at 3 exposure durations (triangles, 1 month; circles, 2 months; plus signs. 4 months). Symbols denote the geometric group means, the individual observations are not plotted here. The background ChE levels increase with age, while the CED decreases with exposure duration.
1963). The same data may be used to propose informed distributions for these assessment factors reflecting betweenchemical variability. These distributions may be applied in a probabilistic risk assessment approach (Baird et al., 1996; Slob and Pieters, 1998; Swartout et al., 1998) . Most of the studies that consider historical data focus on NOAEL ratios, where pairs of NOAELs (for the same compound) are collected associated with two situations (e.g., chronic vs. subchronic or mouse vs. rat). The obtained distributions of NOAEL ratios may be considered as estimates of the uncertainty distributions of assessment factors in a probabilistic risk assessment framework. The observed NOAEL ratio distributions, however, may be inaccurate in estimating the assessment factor distributions (Brand et al., 1999) . For example, the geometric standard deviation (GSD) of observed NOAEL ratios includes estimation errors of the NOAELs, resulting in overestimation of the dispersion of the relevant assessment factor distribution.
Instead of using ratios of NOAELs, assessment factor distributions could be estimated by ratios of CEDs. This appears a better approach for several reasons. First, a NOAEL is the dose at which effects could not be observed, and therefore depends to a large extent on the particular experimental conditions (including sample size, dose spacing, experimental noise). Thus, a NOAEL ratio can easily differ from one, even if the dose-response relationships related to both situations (associated with numerator and denominator) were in reality identical. A more fundamental problem of a NOAEL ratio is that it is not possible to define a (biological) entity that it intends to estimate. This makes it a scientifically unsound approach.
A CED ratio, on the other hand, does estimate a clearly defined entity: it estimates the dose factor needed in one situation (or population) to make its response, in terms of a particular CES, equal to the other situation (or population). Thus, the CED ratio may be regarded as an analogue to the toxicity equivalence factor, or potency factor. Since values for CES cannot be precisely defined, and are open to debate and future insights, the concept of a CED ratio has only practical meaning when its value does not depend on the particular CES, at least in the range of smaller values of CES. This assumption always needs to be checked before assessing the CED ratio. The methodology discussed in this article has the advantage that checking this assumption is inherent in it: when two dose-response data sets can be described by the same model, with parameters a and b possibly being different, the assumption is fulfilled. The estimation of a CED ratio is illustrated in the following example.
Illustrative example 7. Figure 9 shows cholinesterase activity as a function of dose, observed in two studies using different species. Model 5 was fitted to both species simultaneously, allowing for parameters a and b to be different between species, while parameters c and d are assumed equal. The data for both species appear to be adequately described by this model. By accepting this model, the assumption that the ratio of CEDs for both species does not depend on the CES chosen is fulfilled.
In this example, the CEDs associated with a 20% reduction in AChE activity were 0.094 and 0.031 mg/kg, and the same ratio of CEDs will be found for any other value of the CES chosen. This ratio can also be calculated by the ratio of the parameters b in both species: 2.28/0.74 ϭ 3.1. Thus, the difference in sensitivity between these two species can be expressed by a single factor, that holds for any effect size, even though the two dose-response curves are visually quite different. Of course, the interspecies difference factor of 3.1 depends on the dose-scale used, in this case mg/kg BW.
As already indicated, collecting more of these factors (for other compounds/endpoints) will inform the distribution of the interspecies adjustment factor. This empirical distribution may be regarded as reflecting the interspecies sensitivity variation among compounds. However, it is inflated by estimation errors, and therefore may be unnecessarily wide. To gain insight into the extent to which this happens, it is helpful to quantify the uncertainty of each of these factors, or CED ratios, e.g., by the bootstrap method . The resulting uncertainty distribution for the CED ratio in this example is shown in Figure 10 . The associated GSD (which may be considered as a geometric standard error for the estimated ratio) is 1.24.
It is not possible to quantify the SE associated with a NOAEL ratio, and a quantitative comparison cannot be made. Nonetheless, it seems obvious that a CED ratio constitutes a more precise estimate than a NOAEL ratio. It may therefore be expected that the distribution of CED ratios collected for many compounds will turn out to be narrower than the analogue distribution for NOAEL ratios, and thus less conservative.
DISCUSSION
This article presents a generic family of dose-response models, together with a formal procedure of model selection based on the likelihood ratio test. Over the past 4 years this methodology has been extensively applied to a large number of (noncancer) toxicity studies, performed at RIVM and TNO in the Netherlands (Piersma et al., 2000; Woutersen et al., 2001) , or obtained from the open literature (Appel et al., 2001; Janssen et al., in preparation) . Thus far, the models of the proposed family were always applicable in analyzing the observed doseresponse data. Apparently, the family of models proposed here is both flexible and comprehensive enough to describe virtually any continuous dose-response data as resulting from toxicity studies. Together with the formal procedure of model selection, this methodology may serve as a generic approach with the important advantage that the analysis and the estimated CEDs are much less dependent on the person who performed the analysis.
Nonetheless, the formal procedure of model selection should be considered as a guideline, and not as a dictating rule. The basic problem of analyzing dose-response data is to decide what part of the observed differences in response levels are due to experimental fluctuations, and what part to real effects from the applied dose. The formal methodology of statistically testing different models only accounts for the random variation between animals. However, it cannot account for the fact that dose groups may differ in response due to other factors than the dose. Unfortunately, toxicologists (and statisticians) often overlook the fact that in a typical toxicity study treatment groups are in fact not replicated. Since in practice it is virtually impossible to completely randomize a study with respect to all relevant aspects, systematic differences in treatments (other than the dose) or in circumstances between the dose groups can always occur. This may result in systematic errors (Cox, 1958) , i.e., systematic deviations in response between dose groups that are not caused by the dose, but by any other experimental factor(s). Such systematic errors may result from obvious factors (e.g., all animals in a dose group share the same cage), or to less obvious ones (e.g., systematic order in section, or in feeding). Further, they may occur in some endpoints but less so in others, in the same study (Woutersen et al., 2001) . The problem of unreplicated dose groups is especially prominent in the NOAEL approach: an observed difference between a dose group and the controls could be caused by systematic errors between the treatment groups, while a real dose effect could be blurred by it. This problem is attenuated somewhat when the data are analyzed by dose-response modeling. First, one will be more aware of it by considering the dose-response pattern as a whole: a single dose group deviating from the general pattern may alert one to this possibility. Second, compared to the 2-by-2 comparisons in the NOAEL approach, fitting a model to all dose groups simultaneously reduces the influence of a single deviating dose group, especially in multiple dose studies. But nonetheless, the problem of systematic errors between treatment groups could lead to spurious model fits. Therefore, the formal procedure of model selection should not be taken as a dictating principle in all circumstances: biological arguments may overrule it and lead to another model selection. But, of course, these arguments must be made explicit, so that other experts can judge their plausibility.
The problem of systematic errors in (dose) groups has an important bearing on the issue of nonmonotonous dose-response relationships. When we consider a typical toxicity study with three dose levels and a control group, it is easy to see that systematic errors between treatment groups can lead to nonmonotonous dose response data that are enforced by statistical significance. Therefore, this type of study can never provide evidence that the true dose-response relationship is really non -FIG. 10 . Uncertainty distribution for the ratio of CEDs associated with Fig. 9 , which is symmetrical on log-scale.
monotonous. Real evidence for a nonmonotonous dose-response relationship can only be given by multiple dose studies: to exclude systematic errors between treatment groups as an explanation, a nonmonotonous dose-response relationship needs to be substantiated by various consecutive dose groups. And even then, one needs to make sure that the study protocol did not contain any systematic order in the consecutive dose groups.
Whatever the plausibility of nonmonotonous dose-response relationships, be it in the lower (hormesis) or in the higher dose-range (qualitative changes in physiology), we never found, in the hundreds of dose-response data sets analyzed, compelling reasons to extend the family of models with nonmonotonous members. As a matter of fact, in the multiple dose studies (i.e., studies having the potential to detect hormesis) that we analyzed the data gave evidence for monotonous rather than for nonmonotonous relationships (see also several of the illustrative examples). Further, it should be noted that the number of regression parameters that needs to be estimated would further increase when extending the model family with nonmonotonous members. A sensible standpoint appears to be to stick to monotonous dose-response models, unless this is clearly inadequate a priori (e.g., micronutrients), or shown to be inadequate by convincing data. But, as already indicated, a nonmonotonous dose-response relationship is more difficult to assess, and the standard OECD design is not adequate for that purpose.
One of the arguments that has been raised against the benchmark approach is that it strongly hinges on the assumed doseresponse model that was fitted, while the nature of the "true" dose-response model remains unknown. Indeed, different models may result in different (point estimates) of the CED. The proposed family of models and the associated methodology described in this article aims to solve this by providing for a formal method such that different persons analyzing the same data set get the same result (unless they have reason to deviate from the formal method, as discussed above). However, when any other family of models would result in highly different CED estimates, there would be not much ground to regard the proposed methodology, formal as it may be, as a tool that deserves general acceptance. After all, the family of models presented here was only based on a number of general considerations, without any firm scientific substantiation, using knowledge on toxicological mechanisms, for instance. Yet, this is the only thing that can be done: if at all known, toxicological mechanisms are too variable to be captured in a single model. Indeed, the nature of the "true" dose-response model remains unknown, and in such a situation the purpose of using a model can be no more than describing the data. Filling gaps between data points can only be done with a model that contains information (e.g., on the underlying mechanisms). As long as we have to work with models that basically do not contain any information, only the quality of the data determines the quality of the outcome. Therefore, fitting a model to dose-response data is solely intended to smooth the fluctuations in the data, and to provide for a formal method for yielding a point estimate of the parameter of interest (the CED), together with a confidence interval. Such "black box" models should not add anything to the data; they should only follow them. Therefore, a reliable estimate of the CED depends on the quality of the data rather than on the model chosen. When the data show gaps, the model gets the freedom to go its own way, which may be a wrong one, as illustrated by Figures 11 and 12. 
FIG. 11.
Model 5 fitted to dose-response data according to the OECD design, illustrating that the data gaps leave too much freedom to the model: the points at which the response changes is not really supported by data. Compare with Figure 12 , where intermediate data points are available.
FIG. 12.
Model 5 fitted to the same dose-response data as Figure 11 , but extended with data from 6 more dose groups. In this situation there is much less doubt that the fitted model is close to the true dose-response relationship.
The point that it is primarily the data and not the model that governs the outcome is further illustrated by reanalyzing the data of Figure 12 by leaving out the three highest dose groups, as shown in Figure 13 . In this situation the information that the dose-response levels off is lost, and, indeed, Model 5 is found to be not significantly better than any of the other models. Instead, Model 3 would be selected for these data, based on the log-likelihood criterion. Yet, even though the dose-response relationship is in fact sigmoidal and Model 3 is not, fitting Model 3 results in almost the same estimate for the CED, at a CES of 5%. As long as the model is not used for extrapolation outside the range of observation, the only thing that matters is whether the model accurately follows the data.
In conclusion, the critical question is how do we know that the data contain sufficient information to have faith in the fitted model? This issue needs to be further investigated, and in our group this is currently done by computer simulations. But already a number of situations can be formulated giving ground for questioning the reliability of the fitted model:
• There are no more than two or three dose groups showing different response levels.
• The number of (regression) parameters estimated is equal to (or even greater than) the number of dose groups (as in Fig.  11 ).
• Not all elements of the Hessian matrix can be calculated.
• One of the correlations between the parameters is extremely high.
• The log-likelihood profile shows an irregular (i.e., not close to parabolic) shape, e.g., it flattens when moving away from the MLE, and then suddenly drops.
• Different start values for the parameters result in different estimates, i.e., there are local optima in the likelihood function.
• The algorithm has difficulty in finding convergence, or does not succeed in converging at all after trying different start values.
When such indications of insufficient information in the data do not occur, visual inspection of the data with the fitted model should give some confidence that the model accurately describes the data, without leaving the possibility that the true dose-response relationship could as well be fairly different.
To implement the proposed methodology in routine toxicity testing, it is important that easy-to-use software is available. The software (PROAST) that is currently used at RIVM is meant to be made publicly available, as soon as the userinterface has been finished.
APPENDIX
Nonlinear Regression
The models proposed here are, in statistical terminology, nonlinear (strictly, Models 3, 4, and 5 are). A nonlinear model can only be fitted using an iterative algorithm. Such algorithms are now readily available in many software packages, and can usually be applied fairly easily. However, the user should be aware of some idiosyncracies involved in such iterative procedures. Some of these will be discussed briefly.
An iterative algorithm tries to find "better" parameter values by trial and error. It can only start such a procedure when the parameters have values to start with. The user must provide such start values for the parameters, and these should be not too far off. A (interactive) graphical interface therefore is almost indispensable.
The algorithm keeps on varying the parameter values until it decides to stop. There are two possible reasons for the algorithm to stop the trial and error process:
1. The algorithm has converged, i.e., it has found a clear maximum in the log-likelihood function. In this case the associated parameter values can be considered as the maximum likelihood estimates. However, it can happen that the log-likelihood function has not one but more (local) maxima. This means that one may get other results when running the algorithm again, but with other start values. This can be understood by conceiving the likelihood function as a mountainous area with several peaks. Since the algorithm can only "feel" the slope locally, it usually finds the peak that is closest to the starting point. If there are other (higher) peaks, the algorithm may not see those.
2. The algorithm has not converged, i.e., the algorithm was not able to find a clear peak in the likelihood function, but it stops because the maximum number of iterations (trials) is exceeded. This may occur when the information in the data is poor relative to the number of parameters to be estimated. For example, a dose-response model with 5 unknown parameters cannot be estimated with a 4-dose-group study. As another example, the variation between the observations within dose groups may be large compared to the overall change in the dose-response. Such situations are usually associated with high correlations between parameter estimates, i.e., changing the value of one parameter may be compensated by another, leaving the model prediction practically unchanged.
Because of the lognormality assumption, the model is fitted by maximizing the likelihood function based on the normal distribution (data and model on log-scale). This may be achieved by minimizing the sum of squares, or by maximizing the full likelihood function including the variance as a parameter to be estimated simultaneously. In our experience, using Splus as software, the
FIG. 13.
Model 5 fitted to the same dose-response data as Figure 12 , but leaving out the 3 highest dose groups. In this situation model 3 was selected based on the likelihood criterion. Yet, the CED estimate is similar to the one resulting from model 5 in the complete data set.
first approach (Splus function: nls) is faster, but the second (Splus function: nlminb) more stable, i.e., in cases of poor data sets the sum of squares approach is more likely to fail.
